Trial Outcomes & Findings for AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism (NCT NCT05239221)

NCT ID: NCT05239221

Last Updated: 2025-09-08

Results Overview

Number of Treatment Emergent Adverse Events (TEAEs), as assessed by medDRA (v25).

Recruitment status

COMPLETED

Study phase

PHASE1/PHASE2

Target enrollment

132 participants

Primary outcome timeframe

Up to 2 weeks in Part A and Part B, and up to 3 months in Part C

Results posted on

2025-09-08

Participant Flow

A total of 132 subjects were enrolled in the study. Of those, 52 subjects were enrolled in Part A (Phase 1), 52 subjects were enrolled in Part B (Phase 1), and 28 subjects were enrolled in Part C (Phase 2a).

Participant milestones

Participant milestones
Measure	Part A (Cohort A1, 5 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Overall Study STARTED	3	6	6	6	6	6	6	13	8	8	10	8	8	10	12	16
Overall Study COMPLETED	3	6	6	6	6	6	5	13	8	8	8	7	8	10	12	15
Overall Study NOT COMPLETED	0	0	0	0	0	0	1	0	0	0	2	1	0	0	0	1

Reasons for withdrawal

Reasons for withdrawal
Measure	Part A (Cohort A1, 5 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Overall Study Adverse Event	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0
Overall Study Withdrawal by Subject	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1

Baseline Characteristics

AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part A (Cohort A1, 5 ug Dose) n=3 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) n=13 Participants Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) n=8 Participants Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) n=8 Participants Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) n=10 Participants Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) n=8 Participants Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) n=8 Participants Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) n=10 Participants Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) n=12 Participants Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) n=16 Participants Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Total n=132 Participants Total of all reporting groups
Age, Continuous	29.3 years n=5 Participants	38.8 years n=7 Participants	23.7 years n=5 Participants	30.0 years n=4 Participants	26.3 years n=21 Participants	21.0 years n=10 Participants	35.3 years n=115 Participants	29.2 years n=24 Participants	38.3 years n=42 Participants	42.9 years n=42 Participants	39.7 years n=42 Participants	30.1 years n=42 Participants	33.3 years n=36 Participants	32.0 years n=36 Participants	62.7 years n=24 Participants	54.0 years n=135 Participants	37.9 years n=136 Participants
Sex: Female, Male Female	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	2 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	1 Participants n=36 Participants	9 Participants n=24 Participants	12 Participants n=135 Participants	25 Participants n=136 Participants
Sex: Female, Male Male	3 Participants n=5 Participants	6 Participants n=7 Participants	6 Participants n=5 Participants	6 Participants n=4 Participants	6 Participants n=21 Participants	6 Participants n=10 Participants	6 Participants n=115 Participants	13 Participants n=24 Participants	8 Participants n=42 Participants	6 Participants n=42 Participants	9 Participants n=42 Participants	8 Participants n=42 Participants	8 Participants n=36 Participants	9 Participants n=36 Participants	3 Participants n=24 Participants	4 Participants n=135 Participants	107 Participants n=136 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants	0 Participants n=115 Participants	1 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	1 Participants n=42 Participants	2 Participants n=36 Participants	3 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	9 Participants n=136 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	3 Participants n=5 Participants	6 Participants n=7 Participants	6 Participants n=5 Participants	6 Participants n=4 Participants	6 Participants n=21 Participants	5 Participants n=10 Participants	6 Participants n=115 Participants	12 Participants n=24 Participants	8 Participants n=42 Participants	8 Participants n=42 Participants	9 Participants n=42 Participants	7 Participants n=42 Participants	6 Participants n=36 Participants	7 Participants n=36 Participants	12 Participants n=24 Participants	15 Participants n=135 Participants	122 Participants n=136 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	1 Participants n=135 Participants	1 Participants n=136 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	1 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	2 Participants n=136 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	2 Participants n=42 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	3 Participants n=136 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants
Race (NIH/OMB) Black or African American	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	3 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	3 Participants n=136 Participants
Race (NIH/OMB) White	3 Participants n=5 Participants	5 Participants n=7 Participants	5 Participants n=5 Participants	5 Participants n=4 Participants	5 Participants n=21 Participants	5 Participants n=10 Participants	6 Participants n=115 Participants	10 Participants n=24 Participants	8 Participants n=42 Participants	5 Participants n=42 Participants	10 Participants n=42 Participants	7 Participants n=42 Participants	3 Participants n=36 Participants	7 Participants n=36 Participants	12 Participants n=24 Participants	16 Participants n=135 Participants	112 Participants n=136 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=10 Participants	0 Participants n=115 Participants	3 Participants n=24 Participants	0 Participants n=42 Participants	1 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	2 Participants n=36 Participants	2 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	12 Participants n=136 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=24 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=42 Participants	0 Participants n=36 Participants	0 Participants n=36 Participants	0 Participants n=24 Participants	0 Participants n=135 Participants	0 Participants n=136 Participants
Region of Enrollment Hungary	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	0 participants n=21 Participants	0 participants n=10 Participants	0 participants n=115 Participants	0 participants n=24 Participants	0 participants n=42 Participants	0 participants n=42 Participants	0 participants n=42 Participants	0 participants n=42 Participants	0 participants n=36 Participants	0 participants n=36 Participants	9 participants n=24 Participants	6 participants n=135 Participants	15 participants n=136 Participants
Region of Enrollment Spain	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	0 participants n=21 Participants	0 participants n=10 Participants	0 participants n=115 Participants	0 participants n=24 Participants	0 participants n=42 Participants	0 participants n=42 Participants	0 participants n=42 Participants	0 participants n=42 Participants	0 participants n=36 Participants	0 participants n=36 Participants	3 participants n=24 Participants	4 participants n=135 Participants	7 participants n=136 Participants
Region of Enrollment France	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants	0 participants n=4 Participants	0 participants n=21 Participants	0 participants n=10 Participants	0 participants n=115 Participants	0 participants n=24 Participants	0 participants n=42 Participants	0 participants n=42 Participants	0 participants n=42 Participants	0 participants n=42 Participants	0 participants n=36 Participants	0 participants n=36 Participants	0 participants n=24 Participants	6 participants n=135 Participants	6 participants n=136 Participants
Region of Enrollment Netherlands	3 participants n=5 Participants	6 participants n=7 Participants	6 participants n=5 Participants	6 participants n=4 Participants	6 participants n=21 Participants	6 participants n=10 Participants	6 participants n=115 Participants	13 participants n=24 Participants	8 participants n=42 Participants	8 participants n=42 Participants	10 participants n=42 Participants	8 participants n=42 Participants	8 participants n=36 Participants	10 participants n=36 Participants	0 participants n=24 Participants	0 participants n=135 Participants	104 participants n=136 Participants

PRIMARY outcome

Timeframe: Up to 2 weeks in Part A and Part B, and up to 3 months in Part C

Number of Treatment Emergent Adverse Events (TEAEs), as assessed by medDRA (v25).

Outcome measures

Outcome measures
Measure	Part A (Cohort A1, 5 ug Dose) n=3 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) n=13 Participants Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) n=8 Participants Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) n=8 Participants Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) n=10 Participants Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) n=8 Participants Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) n=8 Participants Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) n=10 Participants Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) n=12 Participants Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) n=16 Participants Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Treatment Emergent Adverse Events (TEAEs)	2 Participants	3 Participants	5 Participants	1 Participants	3 Participants	6 Participants	6 Participants	8 Participants	6 Participants	7 Participants	10 Participants	8 Participants	7 Participants	9 Participants	7 Participants	12 Participants

SECONDARY outcome

Timeframe: 24 hours

Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part A

Outcome measures

Outcome measures
Measure	Part A (Cohort A1, 5 ug Dose) n=2 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) n=4 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) n=3 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Observed Maximum Concentration (Cmax) - Part A	6.82 pg/mL Standard Deviation 2.19	11.4 pg/mL Standard Deviation 4.32	24.1 pg/mL Standard Deviation 8.18	26.3 pg/mL Standard Deviation 4.79	28.5 pg/mL Standard Deviation 10.8	57.4 pg/mL Standard Deviation 28.7	37.5 pg/mL Standard Deviation 11.6	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1, Day 14

Population: Data not collected for a few subjects (missing data or site error)

Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part B

Outcome measures

Outcome measures
Measure	Part A (Cohort A1, 5 ug Dose) n=4 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Observed Maximum Concentration (Cmax) - Part B Day 1	20.6 pg/mL Standard Deviation 3.43	19.6 pg/mL Standard Deviation 5.68	23.8 pg/mL Standard Deviation 8.97	42.9 pg/mL Standard Deviation 30.3	124 pg/mL Standard Deviation 105	—	—	—	—	—	—	—	—	—	—	—
Observed Maximum Concentration (Cmax) - Part B Day 14	18.4 pg/mL Standard Deviation 5.37	18.3 pg/mL Standard Deviation 6.78	23.6 pg/mL Standard Deviation 5.50	44.9 pg/mL Standard Deviation 17.9	63.5 pg/mL Standard Deviation 28.3	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1, Day 14, Day 28, Day 84

Population: One (1) subject dropped out in Cohort 2 prior to the extension phase and one (1) subject from Cohort 2 did not participate in the extension phase (data on Day 84). In addition, data not collected for a few subjects (missing data or site error). PK data was not collected in Cohort 1 on Day 84 per the protocol at the time. The protocol was updated following completion of Cohort 1 to collect PK information in Cohort 2 on Day 84.

Observed maximum concentration (Cmax) of AZP-3601 (pg/mL) in Part C.

Outcome measures

Outcome measures
Measure	Part A (Cohort A1, 5 ug Dose) n=12 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) n=16 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Observed Maximum Concentration (Cmax) - Part C Day 1	21.3 pg/mL Standard Deviation 9.20	11.9 pg/mL Standard Deviation 7.82	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Observed Maximum Concentration (Cmax) - Part C Day 14	22.3 pg/mL Standard Deviation 11.7	10.4 pg/mL Standard Deviation 7.73	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Observed Maximum Concentration (Cmax) - Part C Day 28	18.4 pg/mL Standard Deviation 7.42	21.5 pg/mL Standard Deviation 17.9	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Observed Maximum Concentration (Cmax) - Part C Day 84	—	89.9 pg/mL Standard Deviation 63.9	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 24 hours

Area under the plasma-drug concentration time curve (AUC) (pg\*h/mL) in Part A

Outcome measures

Outcome measures
Measure	Part A (Cohort A1, 5 ug Dose) n=2 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) n=4 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) n=3 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Area Under the Plasma-drug Concentration Time Curve (AUC) - Part A	0.399 pg*h/mL Standard Deviation 0.032	5.20 pg*h/mL Standard Deviation 3.38	9.55 pg*h/mL Standard Deviation 4.12	10.4 pg*h/mL Standard Deviation 13.4	16.8 pg*h/mL Standard Deviation 14.7	26.1 pg*h/mL Standard Deviation 16.4	31.7 pg*h/mL Standard Deviation 12.5	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1, Day 14

Population: Data not collected for a few subjects (missing data or site error).

Area Under the Plasma-drug Concentration Time Curve (AUC) (pg\*h/mL) in Part B

Outcome measures

Outcome measures
Measure	Part A (Cohort A1, 5 ug Dose) n=4 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Area Under the Plasma-drug Concentration Time Curve (AUC) - Part B Day 1	3.26 pg*h/mL Standard Deviation 3.20	7.69 pg*h/mL Standard Deviation 5.52	15.8 pg*h/mL Standard Deviation 11.5	43.3 pg*h/mL Standard Deviation 18.1	64.2 pg*h/mL Standard Deviation 56.1	—	—	—	—	—	—	—	—	—	—	—
Area Under the Plasma-drug Concentration Time Curve (AUC) - Part B Day 14	2.02 pg*h/mL Standard Deviation 2.41	4.63 pg*h/mL Standard Deviation 3.29	12.5 pg*h/mL Standard Deviation 4.75	58.8 pg*h/mL Standard Deviation 30.3	51.9 pg*h/mL Standard Deviation 51.6	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1, Day 14, Day 28, Day 84

Population: One (1) subject dropped out in Cohort 2 prior to the extension phase and one (1) subject from Cohort 2 did not participate in the extension phase (data on Day 84). In addition, data not collected for a few subjects (missing data or site error). Pharmacokinetic (PK) data was not collected in Cohort 1 on Day 84 per the protocol at the time. The protocol was updated following completion of Cohort 1 to collect PK information in Cohort 2 on Day 84.

Area Under the Plasma-drug Concentration Time Curve (AUC) (pg\*h/mL) in Part C.

Outcome measures

Outcome measures
Measure	Part A (Cohort A1, 5 ug Dose) n=12 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) n=16 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Area Under the Plasma-drug Concentration Time Curve (AUC) - Part C Day 1	11.9 pg*h/mL Standard Deviation 9.53	4.90 pg*h/mL Standard Deviation 4.87	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Area Under the Plasma-drug Concentration Time Curve (AUC) - Part C Day 14	16.1 pg*h/mL Standard Deviation 14.0	3.99 pg*h/mL Standard Deviation 4.22	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Area Under the Plasma-drug Concentration Time Curve (AUC) - Part C Day 28	12.7 pg*h/mL Standard Deviation 7.58	11.8 pg*h/mL Standard Deviation 11.1	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Area Under the Plasma-drug Concentration Time Curve (AUC) - Part C Day 84	—	116 pg*h/mL Standard Deviation 111	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 24 hours

Levels of calcium corrected for albumin (mg/dL) in Part A

Outcome measures

Outcome measures
Measure	Part A (Cohort A1, 5 ug Dose) n=3 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) n=13 Participants Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Calcium Corrected for Albumin - Part A	9.700 mg/dL Standard Deviation 0.0800	9.375 mg/dL Standard Deviation 0.6215	9.688 mg/dL Standard Deviation 0.3448	9.782 mg/dL Standard Deviation 0.4303	10.065 mg/dL Standard Deviation 0.2934	10.293 mg/dL Standard Deviation 0.5258	10.195 mg/dL Standard Deviation 0.2601	9.634 mg/dL Standard Deviation 0.3030	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 24 hours, Day 14

Population: One (1) subject in Cohort B4 discontinued from the study.

Levels of calcium corrected for albumin (mg/dL) in Part B

Outcome measures

Outcome measures
Measure	Part A (Cohort A1, 5 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) n=10 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Calcium Corrected for Albumin - Part B 24 hours	9.818 mg/dL Standard Deviation 0.3283	9.661 mg/dL Standard Deviation 0.3492	10.121 mg/dL Standard Deviation 0.4320	10.01 mg/dL Standard Deviation 0.30	10.01 mg/dL Standard Deviation 0.41	9.68 mg/dL Standard Deviation 0.21	—	—	—	—	—	—	—	—	—	—
Calcium Corrected for Albumin - Part B Day 14	9.586 mg/dL Standard Deviation 0.3173	9.650 mg/dL Standard Deviation 0.2081	10.055 mg/dL Standard Deviation 0.5916	10.06 mg/dL Standard Deviation 0.59	10.94 mg/dL Standard Deviation 0.97	9.79 mg/dL Standard Deviation 0.24	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1, Day 14, Day 28 and Day 84

Population: One (1) subject dropped out in Cohort 2 prior to the extension phase. In addition to this subject, two (2) subjects from Cohort 1 and one (1) subject from Cohort 2 did not participate in the extension phase (data on Day 84). In addition, data not collected for a few subjects (missing data or site error).

Levels of calcium corrected for albumin (mg/dL) in Part C.

Outcome measures

Outcome measures
Measure	Part A (Cohort A1, 5 ug Dose) n=12 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) n=16 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Calcium Corrected for Albumin - Part C Day 1 (hour 0)	8.44 mg/dL Standard Deviation 0.420	8.61 mg/dL Standard Deviation 0.552	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Calcium Corrected for Albumin - Part C Day 14	8.48 mg/dL Standard Deviation 0.537	8.38 mg/dL Standard Deviation 0.726	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Calcium Corrected for Albumin - Part C Day 28	8.64 mg/dL Standard Deviation 0.491	8.537 mg/dL Standard Deviation 0.697	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Calcium Corrected for Albumin - Part C Day 84	7.95 mg/dL Standard Deviation 0.817	8.73 mg/dL Standard Deviation 0.878	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: 24 hours

Serum phosphate levels (mg/dL) in Part A

Outcome measures

Outcome measures
Measure	Part A (Cohort A1, 5 ug Dose) n=3 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) n=6 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) n=13 Participants Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Serum Phosphate - Part A	3.353 mg/dL Standard Deviation 0.6646	2.882 mg/dL Standard Deviation 0.3884	3.840 mg/dL Standard Deviation 0.5135	3.287 mg/dL Standard Deviation 0.5021	3.908 mg/dL Standard Deviation 0.5051	3.673 mg/dL Standard Deviation 0.4975	3.417 mg/dL Standard Deviation 0.4133	3.641 mg/dL Standard Deviation 0.3637	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1, Day 14

Population: One (1) subject in Cohort B4 discontinued from the study.

Serum phosphate levels (mg/dL) in Part B

Outcome measures

Outcome measures
Measure	Part A (Cohort A1, 5 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) n=8 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) n=10 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Serum Phosphate - Part B Day 1	3.616 mg/dL Standard Deviation 0.1919	3.751 mg/dL Standard Deviation 0.3229	3.824 mg/dL Standard Deviation 0.5421	3.518 mg/dL Standard Deviation 0.3332	3.398 mg/dL Standard Deviation 0.3965	3.65 mg/dL Standard Deviation 0.58	—	—	—	—	—	—	—	—	—	—
Serum Phosphate - Part B Day 14	3.601 mg/dL Standard Deviation 0.2299	3.850 mg/dL Standard Deviation 0.3397	3.603 mg/dL Standard Deviation 0.4738	3.727 mg/dL Standard Deviation 0.3970	3.553 mg/dL Standard Deviation 0.6037	3.74 mg/dL Standard Deviation 0.40	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 1 (H0), Day 14 (H2), Day 28 (H2) and Day 84 (H2)

Population: One (1) subject dropped out in Cohort 2 prior to the extension phase. In addition to this subject, two (2) subjects from Cohort 1 and one (1) subject from Cohort 2 did not participate in the extension phase (data on Day 84). For this reason, data was collected in ten (10) subjects in Cohort 1 and fourteen (14) subjects in Cohort 2 on Day 84. In addition, data not collected for a few subjects (missing data or site error).

Serum phosphate levels (mg/dL) in Part C.

Outcome measures

Outcome measures
Measure	Part A (Cohort A1, 5 ug Dose) n=12 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) n=16 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Serum Phosphate - Part C Day 1	4.12 mg/dL Standard Deviation 0.798	4.53 mg/dL Standard Deviation 0.780	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Serum Phosphate - Part C Day 14	3.43 mg/dL Standard Deviation 0.742	3.95 mg/dL Standard Deviation 0.849	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Serum Phosphate - Part C Day 28	3.50 mg/dL Standard Deviation 0.843	3.82 mg/dL Standard Deviation 0.868	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Serum Phosphate - Part C Day 84	3.60 mg/dL Standard Deviation 0.589	3.80 mg/dL Standard Deviation 6.83	—	—	—	—	—	—	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Day 28 and Day 43

Population: * One (1) subject dropped out in Cohort 2 prior to the extension phase. In addition to this subject, two (2) subjects from Cohort 1 and one (1) subject from Cohort 2 did not participate in the extension phase (data on Day 84). For this reason, data was collected in ten (10) subjects in Cohort 1 and fourteen (14) subjects in Cohort 2 on Day 84. * On Day 84, one (1) patient in Cohort 1 was mistakenly given vitamin D. This patient is included in the nine (9) patients taking no vit D on Day 84.

Daily dose of oral calcium and active vitamin D for patients treated in Part C.

Outcome measures

Outcome measures
Measure	Part A (Cohort A1, 5 ug Dose) n=12 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 5ug of AZP-3601 on Day 1.	Part A (Cohort A2, 10 ug Dose) n=16 Participants Healthy volunteers were administered a single subcutaneous (SC) dose of 10 ug of AZP-3601 on Day 1.	Part A (Cohort A3, 20 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 20 ug of AZP-3601 on Day 1.	Part A (Cohort A4, 40 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 40 ug of AZP-3601 on Day 1.	Part A (Cohort A5, 60 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 60 ug of AZP-3601 on Day 1.	Part A (Cohort A6, 120 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 120 ug of AZP-3601 on Day 1.	Part A (Cohort A7, 90 ug Dose) Healthy volunteers were administered a single subcutaneous (SC) dose of 90 ug of AZP-3601 on Day 1.	Part A (Placebo) Healthy volunteers were administered a single, subcutaneous dose of placebo on Day 1.	Part B (Cohort B1, 10 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 10 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B2, 20 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 20 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B3, 40 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 40 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B4, 60 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 60 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Cohort B5, 80 ug Doses) Healthy volunteers were administered a multiple subcutaneous (SC) doses of 80 ug of AZP-3601, once daily, from Day 1 to Day 14.	Part B (Placebo) Healthy volunteers were administered a multiple subcutaneous (SC) doses of placebo, once daily, from Day 1 to Day 14.	Part C (Cohort C1, Starting Dose of 20 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 20 ug/day, and up-titration of the dose was allowed from Day 14 onwards.	Part C (Cohort C2, Starting Dose of 10 ug/Day) Patients with hypoparathyroidism were treated with a once daily subcutaneous doses of AZP-3601 from Day 1 to Day 84. The starting dose was 10 ug/day, and up-titration of the dose was allowed from Day 14 onwards.
Daily Dose of Oral Calcium and Active Vitamin D - Part C Number of patients taking =< 500 mg/day of calcium on Day 28	9 Participants	12 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Daily Dose of Oral Calcium and Active Vitamin D - Part C Number of patients taking =< 500 mg/day of calcium on Day 84	8 Participants	13 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Daily Dose of Oral Calcium and Active Vitamin D - Part C Number of patients taking no vitamin D on Day 28	10 Participants	12 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Daily Dose of Oral Calcium and Active Vitamin D - Part C Number of patients taking no vitamin D on Day 84	9 Participants	13 Participants	—	—	—	—	—	—	—	—	—	—	—	—	—	—

OTHER_PRE_SPECIFIED outcome

Timeframe: Day 1, Day 14, Day 28 and Day 84

Population: One (1) subject dropped out in Cohort 2 prior to the extension phase. In addition to this subject, two (2) subjects from Cohort 1 and one (1) subject from Cohort 2 did not participate in the extension phase (data on Day 84). For this reason, data was collected in ten (10) subjects in Cohort 1 and fourteen (14) subjects in Cohort 2 on Day 84. In addition, data not collected for a few subjects (missing data or site error).

24 hour calcium excretion rate (mg/24h) in Part C.